The Alkermes Inc. Board of Directors provides significant leadership and guidance within the biopharmaceutical industry. ... Wendy L. Dixon, Ph.D. Dr. Dixon ... Mr. Mitchell is a graduate of College of the Holy Cross (B.A. Economics) and Northeastern University (M.S. Accounting) and he is also a Certified Public Accountant.
Alkermes plc is a pharmaceutical manufacturing and biopharmaceutical company developing innovative medicines to help patients with serious chronic conditions.
May 9, 2011 ... Alkermes and Elan will enter into a shareholder agreement that, among other things, contains a lockup, standstill and voting agreement for Elan's shares of Alkermes plc. Existing shareholders of Alkermes, Inc. will receive one ordinary share of Alkermes plc in exchange for each share of Alkermes, Inc. they ...
Feb 15, 2017 ... Good morning, and welcome to the Alkermes' Fourth Quarter and Year End 2016 Financial Results. My name is Brandon, and I'll be your operator for today. At this time, all participants are in a listen-only mode. Later, we will conduct a question- and-answer session. Please note, this conference is being ...
Nov 7, 2017 ... NEW YORK, Nov. 7, 2017 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alkermes plc ("Alkermes" or the "Company") (NASDAQ: ALKS). Such investors are encouraged to obtain additional information and assist the ...
10:27AM, DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline- January 22, 2018 ACCESSWIRE. Jan-17-18 08:47PM, Netflix, Inc. (NFLX), General Electric Company (GE): Mott Capital Managements Top Winners and Losers of ...
Feb 21, 2018 ... 2018 may be a make-or-break year for biotech Alkermes plc (ALKS), with many critical milestones from drugs that have been in development for years. ... to treat schizophrenia, and a recent licensing deal with Biogen Inc (BIIB) for BIIB098, a multiple sclerosis drug, can all help drive Alkermes stock higher.
Mr. Richard F. Pops has been the Chief Executive Officer of Alkermes PLC since September 2011. Mr. Pops was the Founder of Genomics Collaborative, Inc. He was a Co-founder of Sirtris Pharmaceuticals, Inc. He served as Chief Executive Officer of Alkermes, Inc. from September 2009 to September 2011 an.
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include ...